7733
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Olympus Corporation is a medical technology company operating through two main business segments: Digestive Endoscopy Solutions and Surgical Intervention. The Digestive Endoscopy Solutions segment provides gastrointestinal endoscopes, endoscopic treatment instruments, and related medical services. The Surgical Intervention segment offers urological products, respiratory products, surgical endoscopes, energy devices, otolaryngology products, and gynecological products. Key subsidiaries include Olympus Medical Systems, Olympus Marketing, Olympus America Inc., Olympus Europa SE & Co. KG, Gyrus ACMI, Inc., and Swan EndoSurgical, Inc. The company serves global markets through regional entities in the Americas, Europe, Asia, and specific locations such as Beijing, Suzhou, Korea, Singapore, and Vietnam.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Medical Devices Homepage olympus.co.jp
Sector Healthcare IR page olympus.co.jp
Tags
endoscopy, surgical instruments, urology, respiratory care, energy devices, gynecology, otolaryngology, medical services, Olympus Medical Systems, Olympus Marketing, Aizu Olympus, Shirakawa Olympus, Nagano Olympus, Aomori Olympus, T-Medics, Olympus America Inc., Olympus Europa SE & Co. KG, Olympus Deutschland GmbH, KeyMed (Medical & Industrial Equipment) Ltd., Olympus Winter & Ibe GmbH, Olympus (Beijing) Sales & Service Co. Ltd., Olympus (Suzhou) Medical Device Co. Ltd., Olympus Korea Co. Ltd., Olympus Singapore Pte. Ltd., Olympus Vietnam Co. Ltd., Swan EndoSurgical Inc., Gyrus ACMI Inc., Sony Olympus Medical Solutions, Olympus Corporation of the Americas, Olympus Europa Holding SE, Olympus (China) Co. Ltd., Olympus Corporation of Asia Pacific Limited., Olympus Global Treasury Services Limited
Press page olympus.co.jp/news

Metrics

Valuation  
Market cap ¥ 2.259T
Market cap (USD) $ 14.151B
P/E 24.10
PEG —
P/BV 2.99
P/S 2.12
P/OCF 15.92
P/FCF 35.43
Dividend yield 1.5%
Turnover / mcap —
Returns  
ROE 8.7%
ROI 6.5%
ROIC 6.7%
Profit margin 6.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -22.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.011T 997.332B 936.21B 881.923B 868.867B 730.544B 797.411B 793.862B 788.996B 748.05B 804.578B 764.671B 713.286B 743.851B
Net profit 68.172B 117.855B 242.566B 143.432B 115.742B 12.918B 51.67B 8.147B 46.184B 78.191B 62.594B -8.737B 13.627B 8.02B
Free cash flow 18.162B 125.254B -22.259B 50.92B 107.958B 64.895B 67.615B 5.477B — 42.944B -7.788B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.488K 1.946K 2.207K 2.317K 2.34K 2.291K 1.562K 1.202K 4.039K 4.274K 1.092K 1.116K 3.291K 2.212K
Price performance 12m -0.24 -0.12 -0.05 -0.01 0.02 0.47 0.3 -0.7 -0.05 2.91 -0.02 -0.66 0.49 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 138B 157B 155B 143B 158B 178B 175B 198B 204B 237B
↳ YoY growth -1.9% -1.3% -7.9% +10.4% +13.0% -2.1% +13.1% +3.3% +16.0%
↳ 5y CAGR +2.1% +4.9% +7.4% +8.4%
Borrowings, current (JPY) 68.9B 88.8B 59.7B 81B 31.5B 52.3B 50B 70B 95B 79.9B
Borrowings, non-current (JPY) 218B 159B 122B 200B 324B 334B 290B 230B 134B 160B
Bonds payable (JPY) 25B — — — — — — — — —
Cash and deposits (JPY) 199B 191B 114B 162B 217B 303B 169B 341B 253B 188B
Intangible assets (JPY) 131B 73.4B 69.3B 74.8B 100B 120B 115B 92B 94B 101B
Net debt (borrowings + leases - cash) (JPY) 86.9B 56.7B 66.9B 118B 138B 83.6B 171B -41.3B -23.4B 51.5B
Cash flow detail
Operating cash flow (JPY) 98.6B 84.8B 66.9B 134B 124B 170B 98.5B 42.4B 190B 101B
Purchases of property, plant and equipment (JPY) -43.5B -48.9B -47.1B -37.8B -38.7B -41.7B -47.6B -46.4B -46B -55.6B
Purchases of intangible assets (JPY) -3.71B -14.6B -14.4B -28.2B -20.6B -20.1B -23.1B -18.2B -19.2B -26.9B
Change in receivables (cash effect) (JPY) -660M 1.73B 5.58B 1.28B -9.72B -11B -27B -11.9B -27.7B -30.5B
Change in inventories (cash effect) (JPY) -14.8B -13.2B -14.4B -16.4B 4.02B -2.1B -26.9B -19.1B -3.41B -10.7B
Change in payables (cash effect) (JPY) 1.2B -13.7B 3.11B 731M 7.36B -8.83B 8.77B -5.94B -1.93B 18.5B
Dividends paid (cash effect) (JPY) -5.82B -9.58B -9.56B -10.2B -12.9B -15.4B -17.8B -20.1B -21B -22.6B
Share buybacks (cash effect) (JPY) -8M -3.66B -8M -93.4B -2M -30B -50B -180B -100B -50B
Interest paid (cash effect) (JPY) -7.65B -6.38B -4.62B -3.69B -3.36B -4.29B -5.39B -4.8B -4.19B -4.05B
Income taxes paid (cash effect) (JPY) -7.16B — — — — — — — — —
Operating cash flow before change in receivables (JPY) 90.9B 93.4B 61.4B 132B 134B 181B 126B 54.2B 218B 131B
Free cash flow (OCF - PPE - intangibles) (JPY) 42.9B 31.7B 5.48B 67.6B 64.9B 108B 27.9B -22.3B 125B 18.2B
Income detail
Research and development expense (JPY) 79.2B — 94B 91.6B 81.8B 85.3B 76.9B 86.4B 104B 110B
↳ 5y CAGR -1.7% +2.6% +6.1%
Total comprehensive income (JPY) 46.7B 63.4B 8B 33.3B 36.7B 161B 197B 316B 113B 130B
Comprehensive income to owners (JPY) 35B 61.2B 8.09B 33.3B 36.7B 161B 196B 316B 113B 130B
Segments
Endoscopic Solutions · Segment operating income (JPY) — — 89.8B 109B 105B 133B 153B 105B 141B —
Gastrointestinal Solutions · Segment operating income (JPY) — — — — — — — — 171B 136B
Imaging · Segment operating income (JPY) — -1.2B -18.3B -10.4B — — — — — —
Medical · Segment operating income (JPY) — 122B 112B — — — — — — —
Scientific Solutions · Segment operating income (JPY) — 6.43B 8.14B 10B 4.95B 17.5B — — — —
Surgical And Interventional Solutions · Segment operating income (JPY) — — — — — — — — 15.3B -15B
Therapeutic Solutions · Segment operating income (JPY) — — 22.2B 26.2B 24.6B 60.8B 63.7B -8.47B 61.5B —
Reported Jun 26, 2018 Jun 25, 2019 Jul 6, 2020 Jul 6, 2020 Jun 21, 2021 Jun 21, 2022 Jun 20, 2023 Jun 20, 2024 Jun 18, 2026 Jun 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2027年3月期 第2四半期 決算参考資料 Bull 0 Bear 0 Results
2027年3月期 第2四半期 連結決算概況 Bull 1 Bear 0 Results

Prompts

Olympus Corporation (ticker 7733), listed in Japan.

ETFs Holding Olympus Corporation

ETF Weight in ETF Shares Market value As of
AIVI 0.25% 13,900 $ 145.307K Jun 30, 2026
DIHP 0.17% 979,000 $ 10.962M Nov 12, 2026
AVSD 0.09% 30,200 $ 335.094K Nov 16, 2026
NTSI 0.07% 31,800 $ 332.43K Jun 30, 2026
DFSI 0.06% 66,900 $ 749.121K Nov 12, 2026
DFAI 0.06% 918,400 $ 10.284M Nov 12, 2026
DXIV 0.06% 11,900 $ 133.252K Nov 12, 2026
AVDE 0.05% 836,200 $ 9.278M Nov 16, 2026
DFIC 0.04% 562,700 $ 6.301M Nov 12, 2026
DFAX 0.03% 313,300 $ 3.508M Nov 12, 2026